FDA warned Saffron USA that its tea and blend products are unapproved new drugs because website claims say they treat diseases.
What happened
FDA reviewed Saffron USA's website in September 2022 and found it took orders for Allergy Blend, Chamomile Tea Petals, Diabetic Support Blend, Orange Blast Tea, and Saffron Loose Tea. The website listed health benefits such as allergy relief, treating diabetes, asthma, cancer prevention, lowering cholesterol, and controlling blood sugar. FDA said these claims make the products drugs intended to cure, mitigate, treat, or prevent disease.
What FDA found
Website claims show the products are intended to cure, mitigate, treat, or prevent disease, which makes them drugs under the law.
section 201(g)(1)(B) of the Act [21 U.S.C. 321(g)(1)(B)]The products are new drugs because they are not generally recognized as safe and effective for the claimed uses.
section 201(p) of the Act [21 U.S.C. 321(p)]The company introduced or delivered the new drugs into interstate commerce without FDA approval.
sections 301(d) and 505(a) of the Act [21 U.S.C. 331(d), 355(a)]The products are misbranded because they lack adequate directions for use by a layperson.
section 502(f)(1) of the Act [21 U.S.C. 352(f)(1)]; 21 CFR 201.5The company introduced or delivered misbranded drugs into interstate commerce.
section 301(a) of the Act [21 U.S.C. 331(a)]
What FDA wants
FDA asks Saffron USA to notify it in writing within 15 working days of the steps taken to address the violations and prevent recurrence, including related documentation. If corrective actions cannot be completed in that time, the company must explain the delay and when it will finish.
Who should pay attention
- tea and herbal blend brands that make health claims
- online sellers of food or beverage products with disease claims
- companies marketing products for diabetes, cancer, or asthma relief without FDA approval
This is a summary. Read the original letter on fda.gov.